NCT06966479Phase 2Active not recruiting

A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)

Study sponsor: Upstream Bio Inc. · UPB

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-09Estimated
Enrollment · participants396Actual
Source updated2026-05-14Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 3 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 436 participants (planned). After: 396 participants (actual).

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview